Mark Litwin

Mark S. Litwin, MD, MPH, is Distinguished Professor of Health Policy & Management, Urology, and Nursing at UCLA, where for 14 years he served as Chair of the Department of Urology. Dr. Litwin holds a Bachelor’s Degree in Economics from Duke University an MD from Emory University. He trained in surgery and urology at Harvard Medical School's Brigham and Women’s Hospital. He was a Robert Wood Johnson Clinical Scholar at RAND and UCLA, where he earned his MPH. He is a translational population scientist who has authored original articles, reports, reviews, and book chapters in urologic oncology and health services research. Dr. Litwin published the first validated quality-of-life instrument to track outcomes in men with prostate cancer and has been an international leader in this area. His research includes medical outcomes assessment, quality of care, health-related quality of life, epidemiology, costs and resource utilization, patient preferences, access, and value for malignant and benign diseases in urology. Dr. Litwin’s former fellows hold academic positions at institutions throughout the world. 

He was awarded the American Urological Association’s Gold Cystoscope for his work in establishing the discipline of urological health services research. He also received the AUA Foundation’s Distinguished Mentor Award in 2010, the AUA Distinguished Service Award in 2011, the Society of Urologic Oncology’s Joseph A. Smith Mentorship Award in 2022, and the Barringer Medal from the American Association of Genito-Urinary Surgeons in 2016. In 2026 he was named Honorary Member of the AUA. Dr. Litwin received the 2021 Sherman M. Mellinkoff Award, the highest honor given by the medical faculty at UCLA. His work has been funded by the NIDDK, NCI, Department of Defense, American Cancer Society, California Department of Public Health, and other organizations. He was continuously NIH-funded from 1997 until 2025, when the current Administration cancelled his diversity-focused T32 training grant in cancer outcomes research. His current grants include a $130 million California-funded program that provides prostate cancer care for low-income uninsured men in California, now in its 25th year; and a Movember-funded international registry of prostate cancer outcomes. For 14 years he led Urologic Diseases in America, a $24 million epidemiologic study funded by the NIDDK. He teaches in UCLA’s Schools of Public Health, Medicine, and Nursing and practices urologic oncology at UCLA.

Areas of Interest

• Quality of Care
• Medical Outcomes
• Health-Related Quality of Life
• Resource Use
• Urological Diseases
• Prostate Cancer